HK68996A - Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent - Google Patents

Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent Download PDF

Info

Publication number
HK68996A
HK68996A HK68996A HK68996A HK68996A HK 68996 A HK68996 A HK 68996A HK 68996 A HK68996 A HK 68996A HK 68996 A HK68996 A HK 68996A HK 68996 A HK68996 A HK 68996A
Authority
HK
Hong Kong
Prior art keywords
compound
oxepin
dihydrodibenz
group
solution
Prior art date
Application number
HK68996A
Other languages
English (en)
French (fr)
Inventor
Oshima Etsuo
Kumazawa Toshiaki
Otaki Shizuo
Obase Hiroyuki
Ohmori Kenji
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=12725992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK68996(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Publication of HK68996A publication Critical patent/HK68996A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (9)

1. Dibenz[b,e]oxepin-Verbindung der Formel (I) in der der Rest A eine Carboxylgruppe, einen gerad- oder verzweigtkettigen C1-C6-Alkoxycarbonylrest, einen Rest der Formel -CONHOH oder -CONR1 R2 bedeutet, in der R1 und R2 gleich oder verschieden sind und ein Wasserstoffatom oder einen gerad- oder verzweigtkettigen C1-C6-Alkylrest darstellen;
Y die Bedeutung -(CH2)m-, -CHR3-(CH2)m- oder -CR4 =CR5-(CH2)m- hat, wobei R3 einen gerad- oder verzweigtkettigen C1-C6-Alkylrest, oder einen Niederalkylrest bedeutet, R4 und R5 gleich oder verschieden sind und ein Wasserstoffatom oder einen gerad- oder verzweigtkettigen C1-C6-Alkylrest darstellen und m den Wert 1, 2, 3 oder 4 hat, der den Substituenten in 2- oder 3-Stellung am Hauptkern darstellt, wobei die linke Seite des Restes Y an den Benzolring gebunden ist,
X die Gruppen = N- oder = CH- bedeutet,
n den Wert 0, 1, 2, 3 oder 4 hat,
Z eine 4-Methylpiperazino-, 4-Methylhomopiperazino-, Piperidino-, Pyrrolidino-, Thiomorpholino-, Morpholinogruppe oder den Rest mit der Formel -NR6R7 bedeutet, in der R6 und R7 gleich oder verschieden sind und ein Wasserstoffatom oder einen gerad- oder verzweigtkettigen Ci-6-Alkylrest bedeuten und das Symbol eine Doppelbindung bedeutet, und pharmazeutisch verträgliche Salze davon.
2. Verbindung nach Anspruch 1, wobei das Salz ausgewählt ist aus einem Säureadditionssalz, Metallsalz, Ammoniumsalz, organischen Aminadditionssalz und Aminosäureadditionssalz.
3. Verbindung nach Anspruch 1, wobei der Rest A ausgewählt ist aus gerad- oder verzweigtkettigen Ci - C6-Alkoxycarbonylresten, dem Rest der Formel -CONR1R2 und der Carboxylgruppe, Y in der 2-Stellung des Hauptkerns gebunden ist, X ausgewählt ist aus den Gruppen = N- und = CH-, n den Wert 1 oder 2 hat und Z ausgewählt ist aus der Dimethylamino-, Diethylamino-, Methylamino-, Amino-, Morpholino- und Thiomorpholinogruppe.
4. Verbindung nach Anspruch 3, wobei der Rest Y ausgewählt ist aus -(CH2)m-, und -CH = CH-(CH2)m-und m den Wert 1 oder 2 hat.
5. Verbindung nach Anspruch 4, wobei der Rest A eine Carboxylgruppe bedeutet und X die Gruppe = CH- darstellt.
6. Verbindung nach Anspruch 1, wobei der Rest der Formel -Y-A die Carboxymethyl- oder 2-Carboxyethylgruppe bedeutet, X die Gruppe = CH- bedeutet und n den Wert 2 hat und Z ausgewählt ist aus der Dimethylamino-, Diethylamino-, Methylamino-, Amino-, Morpholino- und Thiomorpholinogruppe.
7. Verbindung nach Anspruch 1, wobei der Rest der Formel -Y-A die Gruppe 2-CH2COOH bedeutet, X die Gruppe = CH-bedeutet, n den Wert 2 hat und Z eine Dimethylaminogruppe darstellt.
8. Verbindung nach Anspruch 1, wobei der Rest der Formel -Y-A die Gruppe 2-CH2CH2COOH bedeutet, X die Gruppe = CH-bedeutet, n den Wert 2 hat und Z eine Dimethylaminogruppe darstellt.
9. Verwendung einer Verbindung gemäß einem der Ansprüche 1 bis 8 zur Herstellung von Arzneimitteln zur therapeutischen Behandlung von allergischen und entzündlichen Erkrankungen.
HK68996A 1986-03-03 1996-04-18 Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent HK68996A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4567686 1986-03-03

Publications (1)

Publication Number Publication Date
HK68996A true HK68996A (en) 1996-04-26

Family

ID=12725992

Family Applications (1)

Application Number Title Priority Date Filing Date
HK68996A HK68996A (en) 1986-03-03 1996-04-18 Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent

Country Status (7)

Country Link
US (1) US5116863A (de)
EP (1) EP0235796B2 (de)
JP (1) JPS6310784A (de)
DE (1) DE3778734D1 (de)
ES (1) ES2038608T5 (de)
HK (1) HK68996A (de)
MX (1) MX9203155A (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882351A (en) * 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) * 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
US5242931A (en) * 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
US4999363A (en) * 1988-06-09 1991-03-12 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
TW209861B (de) * 1989-08-25 1993-07-21 Hoechst Roussel Pharma
US5840749A (en) * 1989-08-25 1998-11-24 Hoechst Marion Roussel, Inc. N-hydroxy-dibenz b,e!oxepinalkylamines, N-hydroxy-dibenz b,e!oxepinalkanoic acid amides and related heterocyclic analogues
US5574173A (en) * 1993-12-06 1996-11-12 Schering Corporation Tricyclic derivatives, compositions and methods of use
DE69427023T2 (de) * 1993-12-28 2001-10-31 Meiji Seika K.K., Tokio/Tokyo Tricyclische benzazepin-und benzothiazepin derivate
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
WO1997014672A1 (en) * 1995-10-16 1997-04-24 Kyowa Hakko Kogyo Co. Ltd. Triciclic compounds
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU729415B2 (en) 1996-07-12 2001-02-01 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
HUP0002461A3 (en) 1997-04-15 2003-01-28 Kyowa Hakko Kogyo Kk Tricyclic benzothiepin a benzoxepin derivatives and pharmaceutical compositions thereof
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
AU2331999A (en) 1998-01-21 1999-08-09 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
CA2318088A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
DE69900207T2 (de) * 1998-07-14 2001-11-22 Alcon Laboratories, Inc. Verwendung von 11-(3-dimethylaminopropyliden)-6,11-dihydrodibenz[b,e]oxepin-2-essigsäure und deren pharmazeutisch annehmbaren salzen zur herstellung eines medikaments zur behandlung nicht-allergisch-bedingten augenentzündungen und zur prevention der okularen neovaskularisation
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6174914B1 (en) 1999-06-15 2001-01-16 Alcon Laboratories, Inc. Method of inhibiting cytokine release from human ocular cells
US20040097486A1 (en) * 1999-11-18 2004-05-20 Yanni John M. Use of an H1 antagonist and a safe steroid to treat eye conditions
US6375973B2 (en) 2000-01-25 2002-04-23 Alcon Universal Ltd. Ophthalmic anti-allergy compositions suitable for use with contact lenses
AU5722701A (en) 2000-05-19 2001-12-03 Alcon Universal Ltd Aniline disulfide derivatives for treating allergic diseases
DK1282599T3 (da) 2000-05-19 2006-07-31 Alcon Inc Disulfidderivater, der er egnede til behandling af allergiske sygdomme
JP2003534274A (ja) 2000-05-19 2003-11-18 アルコン，インコーポレイテッド アレルギー性疾患を処置するための、ベンズアミドジスルフィド誘導体を含む組成物
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
TWI231759B (en) 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
JP4022519B2 (ja) * 2001-11-13 2007-12-19 協和醗酵工業株式会社 そう痒の予防または治療剤
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
KR20050044550A (ko) * 2001-12-05 2005-05-12 알콘, 인코퍼레이티드 비염 치료를 위한 η1 길항제 및 안전한 스테로이드제의용도
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
WO2005011674A1 (ja) * 2003-08-05 2005-02-10 Kyowa Hakko Kogyo Co., Ltd. 気管支喘息の予防及び／または治療剤
US20050209312A1 (en) * 2004-03-19 2005-09-22 Bausch & Lomb Incorporated Carboxylic acid derivatives of doxepin formulations preserved with low-irritation preservative
WO2005102313A1 (ja) * 2004-04-21 2005-11-03 Kyowa Hakko Kogyo Co., Ltd. 慢性副鼻腔炎の予防および／または治療剤
BRPI0512732A (pt) * 2004-06-28 2008-04-08 Alcon Inc formulações tópicas para tratamento de doenças alérgicas
CA2573915A1 (en) * 2004-07-16 2006-01-26 Kyowa Hakko Kogyo Co., Ltd. Preventive and/or therapeutic agent for sleeping disorder
ES2253996B1 (es) * 2004-07-28 2007-08-16 Urquima, S.A. Procedimiento para la preparacion del acido 11-((z)-3-(dimetilamino)propiliden)-6,11-dihidrodibenz(b,e)oxepinacetico.
MX2007005845A (es) * 2004-11-24 2007-07-04 Alcon Inc Metodo para entregar rocio nasal.
US20060280821A1 (en) * 2005-04-04 2006-12-14 Foo Lai Y Method of treating inflammation disorders using extracts of passion fruit
ES2437077T3 (es) * 2005-07-08 2014-01-08 Senju Pharmaceutical Co., Ltd. Preparado oftálmico de absorción percutánea que comprende olopatadina
CA2634665A1 (en) 2005-12-22 2007-10-25 Medichem, S.A. Crystalline polymorphic forms of olopatadine hydrochloride and processes for their preparation
WO2007105234A2 (en) * 2006-03-14 2007-09-20 Usv Limited A PROCESS FOR THE PREPARATION OF ISOMERS OF 11-[3-(DIMETHYLAMINO)PROPYLIDENE]-6, 11-DIHYDRODIBENZ [b, e] OXEPIN-2-ACETIC ACID HYDROCHLORIDE AND POLYMORPHS THEREOF
US7950020B2 (en) * 2006-03-16 2011-05-24 Ntt Docomo, Inc. Secure operating system switching
US7687646B2 (en) * 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
ES2409840T3 (es) * 2006-10-02 2013-06-28 Sumitomo Chemical Co., Ltd Proceso para la preparación de olopatadina
JP5139016B2 (ja) * 2006-10-02 2013-02-06 住友化学株式会社 オキソジベンゾオキセピン酢酸第３級アルキルエステルの製造方法
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
PT2114367E (pt) 2007-02-07 2016-02-01 Novartis Ag Formulações de olopatadina para administração nasal tópica
JP5139104B2 (ja) * 2007-02-16 2013-02-06 住友化学株式会社 ジベンゾオキセピン化合物の製造方法
WO2008099900A1 (ja) * 2007-02-16 2008-08-21 Sumitomo Chemical Company, Limited ジベンゾオキセピン化合物の製造方法
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2009031682A1 (ja) 2007-09-06 2009-03-12 Kyowa Hakko Kirin Co., Ltd. ジベンゾ[b,e]オキセピン誘導体含有点眼剤
US20090069413A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched olopatadine
JP5248078B2 (ja) * 2007-10-05 2013-07-31 住友化学株式会社 ジベンゾオキセピン化合物の製造方法
EP2666770A1 (de) * 2008-07-16 2013-11-27 Crystal Pharma S.A.U Verfahren zur Herstellung von Olopatadin und Zwischenprodukten
WO2010013805A1 (ja) 2008-08-01 2010-02-04 日本臓器製薬株式会社 アミノプロピリデン誘導体
US8642069B2 (en) * 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
JP5503877B2 (ja) 2009-01-30 2014-05-28 住友化学株式会社 ジベンゾオキセピン化合物の製造方法
WO2010089268A2 (en) * 2009-02-05 2010-08-12 Zach System S.P.A. Process for preparing olopatadine and/or a pharmaceutically acceptable salt thereof
IT1397503B1 (it) 2009-04-21 2013-01-16 F S I Fabbrica Italiana Sint Processo per la preparazione di olopatadina
PL2453872T3 (pl) 2009-07-17 2013-12-31 Alcon Res Ltd Olopatadyna w postaci spreju do donosowego podawania dzieciom
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
WO2011033532A1 (en) 2009-09-17 2011-03-24 Indoco Remedies Limited Process for preparation of olopatadine hydrochloride
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
WO2011128911A2 (en) * 2010-04-12 2011-10-20 Msn Laboratories Limited Improved process for ll-[(z)-3-(dimethylamino)propyiidenel-6-ll- dihydrodibenz[b,el oxepin-2-aceticacid
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
TW201206936A (en) 2010-07-19 2012-02-16 Alcon Res Ltd Methods and compositions for the treatment of allergy
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
TW201336527A (zh) 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
CN103664861B (zh) * 2013-12-18 2018-01-30 北京华禧联合科技发展有限公司 一种用高活性有机锌试剂制备盐酸奥洛他定的新方法
JP7424115B2 (ja) * 2019-06-26 2024-01-30 住友化学株式会社 エステル化合物の製造方法
CN111548369B (zh) * 2020-05-29 2023-02-28 内蒙古京东药业有限公司 一种简便制备高纯度奥洛他定盐酸盐中间体的方法
CN112457287B (zh) * 2020-12-09 2024-02-06 重庆西南制药二厂有限责任公司 一种e-奥洛他定的制备方法
CN114380783B (zh) * 2022-01-18 2023-02-10 梯尔希（南京）药物研发有限公司 一种奥洛他定氘标记代谢物的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE641498A (de) * 1962-03-13
US3420851A (en) * 1962-12-19 1969-01-07 Pfizer & Co C Novel dibenzoxepines
FR88751E (de) * 1963-07-09 1967-06-07
SE368825B (de) * 1963-10-14 1974-07-22 Pfizer
DE1543346A1 (de) * 1966-04-30 1969-09-25 Boehringer Mannheim Gmbh Verfahren zur Herstellung basischer Derivate des Dibenzoxepins und Dibenzothiepins
US4585788A (en) * 1973-09-06 1986-04-29 American Hoechst Corporation 6,11-dihydrodibenz[b,e]oxepin-acetic acids and derivatives
US4282365A (en) * 1978-11-24 1981-08-04 Merck & Co., Inc. Dibenz[b,e]oxepin compounds
JPS56150083A (en) * 1980-04-22 1981-11-20 Kyowa Hakko Kogyo Co Ltd Novel dibenzo b,e oxepin derivative
US4396550A (en) * 1980-04-22 1983-08-02 Kyowa Hakko Kogyo Co., Ltd. Dibenz [b,e] oxepin derivatives
EP0069810B1 (de) * 1981-07-09 1986-12-03 Merck & Co. Inc. Dibenzoxepine, ihre Herstellung, diese Verbindungen enthaltende Zusammensetzungen und ihre Verwendung bei der Behandlung von allergischen Zuständen
JPS5821679A (ja) * 1981-07-31 1983-02-08 メルク　エンド　カムパニー　インコーポレーテツド ジベンツ〔ｂ，ｅ〕オキセピン化合物
JPS58126883A (ja) * 1982-01-25 1983-07-28 Kyowa Hakko Kogyo Co Ltd ジベンゾ〔ｂ，ｅ〕オキセピン誘導体を含有してなる抗喘息剤
JPS59227879A (ja) * 1983-06-10 1984-12-21 Kyowa Hakko Kogyo Co Ltd ジベンゾ［ｂ，ｅ］オキセピン誘導体
JPS6028972A (ja) * 1983-06-29 1985-02-14 Kyowa Hakko Kogyo Co Ltd ジベンゾ［ｂ，ｅ］オキセピン誘導体
EP0188802A3 (de) * 1984-12-26 1986-08-20 Kyowa Hakko Kogyo Co., Ltd. Dibenz(b,e)oxepin-Derivat und antiallergisches Mittel
GB8520662D0 (en) * 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds

Also Published As

Publication number Publication date
JPH0586925B2 (de) 1993-12-14
EP0235796A2 (de) 1987-09-09
EP0235796B1 (de) 1992-05-06
MX9203155A (es) 1992-07-01
EP0235796B2 (de) 1997-03-12
ES2038608T5 (es) 1997-07-16
JPS6310784A (ja) 1988-01-18
EP0235796A3 (en) 1988-09-21
DE3778734D1 (de) 1992-06-11
US5116863A (en) 1992-05-26
ES2038608T3 (es) 1993-08-01

Similar Documents

Publication Publication Date Title
EP0235796B1 (de) Dibenzo[b,e]oxepin-Derivate sowie antiallergische und entzündunghemmende Mittel
EP0296879B1 (de) Substituierte aromatische Sulfonamide als Mittel gegen Glaukom
DE3888821T2 (de) Tricyclische Verbindungen.
EP0312051B1 (de) Trizyklische Verbindungen
JPH0576447B2 (de)
US4193998A (en) 1,2,3,4,6,7-Hexahydro-11BαH-benzo[a]quinolizine-derivatives
EP0130555A2 (de) Dibenz(b,e)oxepin-Derivate
US4282240A (en) Amino substituted tetrahydrobenzindoles
US4604403A (en) Use of substituted-3(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones for treating grey matter edema
FR2757514A1 (fr) Nouveaux analogues de la camptothecine, des procedes de preparation, leur application comme medicaments et les compositions pharmaceutiques les contenant
US4596821A (en) Treatment of gray matter edema with 3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones
US4605664A (en) Use of substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones for treatment of grey matter edema
US4634717A (en) Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones, useful for treating persons with gray matter edema
US4605663A (en) Use of substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones, for treatment of grey matter edema
US4539326A (en) 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents
US4356186A (en) Acetic acid derivatives and composition containing the same
US4680414A (en) Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones
US4956384A (en) 1,4:3,6-dianhydrosorbitol 2-mononitrate and 5-mononitrate esters and pharmaceutical compositions therefrom
US5075317A (en) Spirofurane derivatives
US4496568A (en) Antiinflammatory thieno [2,3-c]pyridine derivatives
JPS6011711B2 (ja) テトラヒドロチオピラノピラゾ−ル類
CA1337603C (en) Dibenz[b,e]oxepin derivative and antiallergic and antiinflammatory agent
US5310750A (en) Heterocyclic compounds useful as α2 -adrenoceptor antagonists
PL195289B1 (pl) Analog kamptotecyny, związek pośredni, sposób wytwarzania związku pośredniego i zastosowania
IL96168A (en) History of 4-amidino as novel and 4-amidino pirano (C-3,2), preparation and pharmaceutical preparations containing them

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20070302